Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence

Brian L. Cohen, Pablo Gomez, Yohei Omori, Robert C. Duncan, Francisco Civantos, Mark S. Soloway, Vinata B. Lokeshwar, Bal L. Lokeshwar

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Lack of reliable prognostic markers hinders accurate prediction of disease progression in prostate cancer. The inducible proinflammatory enzyme cyclooxygenase-2 (COX-2) is implicated in prostate carcinogenesis, but its role in cancer progression is less clear. We examined whether COX-2 expression evaluated by immunohistochemistry (IHC) in radical prostatectomy (RP) specimens can predict biochemical recurrence. Archival prostate cancer specimens (n = 60) were obtained from patients who underwent RP, but had not received neoadjuvant hormonal therapy. Twenty-three patients had biochemical or clinical recurrence (mean time of recurrence: 38.2 months), and 37 patients were recurrence free (mean follow-up: 95 months). COX-2 expression was determined by IHC, using an anti-COX-2 antibody. Three individuals scored the staining independently, as high- or low-expression. COX-2 was expressed in prostate cancer cells, in adjacent normal glands and in specimens from patients who later progressed. At 62-months follow-up, COX-2 staining predicted progression with 82.4% sensitivity and 81.3% specificity. Sensitivity (86.4%) and specificity (86.7%) improved at ≥ 100-months follow-up. In univariate analysis, Gleason score, preoperative PSA, extraprostatic extension, margin, seminal vesicle invasion, and high COX-2 expression were significant predictors of biochemical recurrence (p < 0.05). In multivariate analysis, preoperative PSA (hazard ratio/unit PSA change 1.080; p = 0.0036) and COX-2 expression (hazard ratio 16.442; p < 0.0001) were independent prognostic indicators. Patients with PSA > 7 ng/ml and high COX-2 expression had the highest probability of recurrence (Kaplan-Meier analysis). COX-2 expression is an independent predictor of prostate cancer progression following RP and underscores the significance of inflammatory factors in this process.

Original languageEnglish
Pages (from-to)1082-1087
Number of pages6
JournalInternational Journal of Cancer
Volume119
Issue number5
DOIs
StatePublished - Sep 1 2006

Fingerprint

Cyclooxygenase 2
Prostatic Neoplasms
Recurrence
Prostatectomy
Immunohistochemistry
Staining and Labeling
Sensitivity and Specificity
Neoadjuvant Therapy
Neoplasm Grading
Seminal Vesicles
Kaplan-Meier Estimate
Disease Progression
Prostate
Carcinogenesis
Antibodies
Enzymes

Keywords

  • Cancer progression
  • Immunohistochemistry
  • Inflammation
  • Multivariate analysis
  • Prognostic indicators
  • PSA
  • Tumor markers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cohen, B. L., Gomez, P., Omori, Y., Duncan, R. C., Civantos, F., Soloway, M. S., ... Lokeshwar, B. L. (2006). Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. International Journal of Cancer, 119(5), 1082-1087. https://doi.org/10.1002/ijc.21749

Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. / Cohen, Brian L.; Gomez, Pablo; Omori, Yohei; Duncan, Robert C.; Civantos, Francisco; Soloway, Mark S.; Lokeshwar, Vinata B.; Lokeshwar, Bal L.

In: International Journal of Cancer, Vol. 119, No. 5, 01.09.2006, p. 1082-1087.

Research output: Contribution to journalArticle

Cohen, BL, Gomez, P, Omori, Y, Duncan, RC, Civantos, F, Soloway, MS, Lokeshwar, VB & Lokeshwar, BL 2006, 'Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence', International Journal of Cancer, vol. 119, no. 5, pp. 1082-1087. https://doi.org/10.1002/ijc.21749
Cohen, Brian L. ; Gomez, Pablo ; Omori, Yohei ; Duncan, Robert C. ; Civantos, Francisco ; Soloway, Mark S. ; Lokeshwar, Vinata B. ; Lokeshwar, Bal L. / Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. In: International Journal of Cancer. 2006 ; Vol. 119, No. 5. pp. 1082-1087.
@article{b97b90d7b32c48828c4b8dab64571a7a,
title = "Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence",
abstract = "Lack of reliable prognostic markers hinders accurate prediction of disease progression in prostate cancer. The inducible proinflammatory enzyme cyclooxygenase-2 (COX-2) is implicated in prostate carcinogenesis, but its role in cancer progression is less clear. We examined whether COX-2 expression evaluated by immunohistochemistry (IHC) in radical prostatectomy (RP) specimens can predict biochemical recurrence. Archival prostate cancer specimens (n = 60) were obtained from patients who underwent RP, but had not received neoadjuvant hormonal therapy. Twenty-three patients had biochemical or clinical recurrence (mean time of recurrence: 38.2 months), and 37 patients were recurrence free (mean follow-up: 95 months). COX-2 expression was determined by IHC, using an anti-COX-2 antibody. Three individuals scored the staining independently, as high- or low-expression. COX-2 was expressed in prostate cancer cells, in adjacent normal glands and in specimens from patients who later progressed. At 62-months follow-up, COX-2 staining predicted progression with 82.4{\%} sensitivity and 81.3{\%} specificity. Sensitivity (86.4{\%}) and specificity (86.7{\%}) improved at ≥ 100-months follow-up. In univariate analysis, Gleason score, preoperative PSA, extraprostatic extension, margin, seminal vesicle invasion, and high COX-2 expression were significant predictors of biochemical recurrence (p < 0.05). In multivariate analysis, preoperative PSA (hazard ratio/unit PSA change 1.080; p = 0.0036) and COX-2 expression (hazard ratio 16.442; p < 0.0001) were independent prognostic indicators. Patients with PSA > 7 ng/ml and high COX-2 expression had the highest probability of recurrence (Kaplan-Meier analysis). COX-2 expression is an independent predictor of prostate cancer progression following RP and underscores the significance of inflammatory factors in this process.",
keywords = "Cancer progression, Immunohistochemistry, Inflammation, Multivariate analysis, Prognostic indicators, PSA, Tumor markers",
author = "Cohen, {Brian L.} and Pablo Gomez and Yohei Omori and Duncan, {Robert C.} and Francisco Civantos and Soloway, {Mark S.} and Lokeshwar, {Vinata B.} and Lokeshwar, {Bal L.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1002/ijc.21749",
language = "English",
volume = "119",
pages = "1082--1087",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence

AU - Cohen, Brian L.

AU - Gomez, Pablo

AU - Omori, Yohei

AU - Duncan, Robert C.

AU - Civantos, Francisco

AU - Soloway, Mark S.

AU - Lokeshwar, Vinata B.

AU - Lokeshwar, Bal L.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Lack of reliable prognostic markers hinders accurate prediction of disease progression in prostate cancer. The inducible proinflammatory enzyme cyclooxygenase-2 (COX-2) is implicated in prostate carcinogenesis, but its role in cancer progression is less clear. We examined whether COX-2 expression evaluated by immunohistochemistry (IHC) in radical prostatectomy (RP) specimens can predict biochemical recurrence. Archival prostate cancer specimens (n = 60) were obtained from patients who underwent RP, but had not received neoadjuvant hormonal therapy. Twenty-three patients had biochemical or clinical recurrence (mean time of recurrence: 38.2 months), and 37 patients were recurrence free (mean follow-up: 95 months). COX-2 expression was determined by IHC, using an anti-COX-2 antibody. Three individuals scored the staining independently, as high- or low-expression. COX-2 was expressed in prostate cancer cells, in adjacent normal glands and in specimens from patients who later progressed. At 62-months follow-up, COX-2 staining predicted progression with 82.4% sensitivity and 81.3% specificity. Sensitivity (86.4%) and specificity (86.7%) improved at ≥ 100-months follow-up. In univariate analysis, Gleason score, preoperative PSA, extraprostatic extension, margin, seminal vesicle invasion, and high COX-2 expression were significant predictors of biochemical recurrence (p < 0.05). In multivariate analysis, preoperative PSA (hazard ratio/unit PSA change 1.080; p = 0.0036) and COX-2 expression (hazard ratio 16.442; p < 0.0001) were independent prognostic indicators. Patients with PSA > 7 ng/ml and high COX-2 expression had the highest probability of recurrence (Kaplan-Meier analysis). COX-2 expression is an independent predictor of prostate cancer progression following RP and underscores the significance of inflammatory factors in this process.

AB - Lack of reliable prognostic markers hinders accurate prediction of disease progression in prostate cancer. The inducible proinflammatory enzyme cyclooxygenase-2 (COX-2) is implicated in prostate carcinogenesis, but its role in cancer progression is less clear. We examined whether COX-2 expression evaluated by immunohistochemistry (IHC) in radical prostatectomy (RP) specimens can predict biochemical recurrence. Archival prostate cancer specimens (n = 60) were obtained from patients who underwent RP, but had not received neoadjuvant hormonal therapy. Twenty-three patients had biochemical or clinical recurrence (mean time of recurrence: 38.2 months), and 37 patients were recurrence free (mean follow-up: 95 months). COX-2 expression was determined by IHC, using an anti-COX-2 antibody. Three individuals scored the staining independently, as high- or low-expression. COX-2 was expressed in prostate cancer cells, in adjacent normal glands and in specimens from patients who later progressed. At 62-months follow-up, COX-2 staining predicted progression with 82.4% sensitivity and 81.3% specificity. Sensitivity (86.4%) and specificity (86.7%) improved at ≥ 100-months follow-up. In univariate analysis, Gleason score, preoperative PSA, extraprostatic extension, margin, seminal vesicle invasion, and high COX-2 expression were significant predictors of biochemical recurrence (p < 0.05). In multivariate analysis, preoperative PSA (hazard ratio/unit PSA change 1.080; p = 0.0036) and COX-2 expression (hazard ratio 16.442; p < 0.0001) were independent prognostic indicators. Patients with PSA > 7 ng/ml and high COX-2 expression had the highest probability of recurrence (Kaplan-Meier analysis). COX-2 expression is an independent predictor of prostate cancer progression following RP and underscores the significance of inflammatory factors in this process.

KW - Cancer progression

KW - Immunohistochemistry

KW - Inflammation

KW - Multivariate analysis

KW - Prognostic indicators

KW - PSA

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=33746329955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746329955&partnerID=8YFLogxK

U2 - 10.1002/ijc.21749

DO - 10.1002/ijc.21749

M3 - Article

C2 - 16557596

AN - SCOPUS:33746329955

VL - 119

SP - 1082

EP - 1087

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -